Hydroxychloroquine for the Treatment of Recurrent, Oligometastatic Prostate Cancer

This phase II trial studies how well hydroxychloroquine works in treating patients with prostate cancer that has come back (recurrent) and has spread to a limited number of sites (oligometastatic). PAR-4 is a protein that causes cell death in cancer cells, but the amount of it made by normal cells is not enough to cause massive cancer cell death. Hydroxychloroquine may increase PAR-4 levels which helps kill more cancer cells.

link